Nelipepimut-S

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Nelipepimut-S
Accession Number
DB06226
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Description
Not Available
Synonyms
  • Nelipepimut S
External IDs
E-75 PEPTIDE / E75 / E75 PEPTIDE
International/Other Brands
NeuVax (Apthera, Inc.)
Categories
Not Available
UNII
7M0A29CD8B
CAS number
160212-35-1

Pharmacology

Indication

Investigated for use/treatment in prostate cancer and breast cancer.

Pharmacodynamics
Not Available
Mechanism of action

NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]

TargetActionsOrganism
UHLA class I histocompatibility antigen, A-2 alpha chainNot AvailableHumans
UHLA class I histocompatibility antigen, A-3 alpha chainNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448. [PubMed:18245541]
  2. Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE: Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17. [PubMed:16783576]
External Links
Wikipedia
E75

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingPreventionCancer, Breast1
3CompletedPreventionBreast Cancer With Low to Intermediate HER2 Expression1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tap binding
Specific Function
Involved in the presentation of foreign antigens to the immune system.
Gene Name
HLA-A
Uniprot ID
P01892
Uniprot Name
HLA class I histocompatibility antigen, A-2 alpha chain
Molecular Weight
40921.59 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tap binding
Specific Function
Involved in the presentation of foreign antigens to the immune system.
Gene Name
HLA-A
Uniprot ID
P04439
Uniprot Name
HLA class I histocompatibility antigen, A-3 alpha chain
Molecular Weight
40840.41 Da

Drug created on March 19, 2008 10:18 / Updated on August 02, 2019 07:49